Skip to content

NAD+ vs NMN vs NR: Which One Should You Actually Take?

One is the working molecule, two are precursors that build it. The three-way comparison in one table — evidence, route, cost per dose, and who each is for.

By Marcus HaleLongevity Research Editor
Updated

4 min read · 10 sources

On this page

Here is the whole comparison in three sentences. NAD+ is the working molecule — the coenzyme your cells actually use — but it is large, charged, and poorly suited to being swallowed intact, which is why "oral NAD+" products lean on absorption claims their trials have not backed 1. NMN and NR are precursors: smaller molecules your cells convert into NAD+ through the salvage pathway, and both have randomized human trials showing they raise blood NAD+ reliably 2 3. So the practical answer for most people is a precursor by mouth — and between the two precursors, NR currently has the deeper trial record, including a dedicated safety study of a branded product, while NMN has real trials of its own and a similar profile 4 5.

The three-way decision

Swipe table to compare all columns →

NAD+ (the molecule)NMN (precursor)NR (precursor)
What it isThe working coenzyme itselfOne step from NAD+Two steps from NAD+ (via NMN)
Raises blood NAD+ in trials?Limited IV biochemistry data; subcutaneous/nasal evidence lackingYes — dose-dependent RCTYes — multiple RCTs incl. branded material
Human safety dataLimited short-term IV data; other routes poorly studiedWell tolerated in trialsDedicated safety RCT up to 1,000 mg/day
Typical cost$93/mo advertised floor to $300+ (prescription routes)Tens of dollars/moTens of dollars/mo
Felt benefits proven?NoNarrow and contested at bestModest at best
The uncomfortable pattern: the more you pay in this category, the less human evidence you get. Prices as advertised on our index, August 2026.

Affiliate partner

MadeMed

NAD+ injection & nasal spray, in 23 states

See MadeMed

The rest of this page earns those three sentences — and covers the option the table is quietly hardest on: paying a premium for NAD+ itself by IV, injection, or nasal spray.

Before comparing products, our plain-language NAD+ introduction explains the difference between needing a coenzyme and benefiting from a commercial treatment.

A similarly named product can be a different intervention: NAD+ and NADH are a cellular redox pair with distinct supplement research.

The relationship, in one step

These are not three competing versions of the same thing. NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental cofactors in biology — central to energy metabolism, DNA-repair enzymes, and sirtuin signaling, and your cells continuously build and recycle it 6 1. NMN (nicotinamide mononucleotide) sits one enzymatic step away from NAD+; NR (nicotinamide riboside) sits one step behind NMN. Take either precursor and your cells do the last step themselves 1. Neither is a peptide, and neither is NAD+ — two confusions that do a lot of quiet work in this category's marketing, which we take apart in is NAD+ a peptide? and NMN vs NAD+.

What the human evidence says, option by option

Oral NR is the best-documented option in the category. It is orally bioavailable in humans 7, chronic supplementation elevates NAD+ in middle-aged and older adults 3, and the branded NIAGEN material has its own randomized safety trial at doses up to 1,000 mg per day — well tolerated over eight weeks 4. That last study is a real differentiator: a dedicated placebo-controlled safety trial of the exact commercial ingredient is something we can point to for no other product on our own supplement rankings.

Oral NMN does the same job with a somewhat younger record. A randomized, multicenter, dose-dependent trial in healthy middle-aged adults found NMN raised blood NAD+ and was well tolerated across doses 5, and its most-cited benefit — improved muscle insulin sensitivity in prediabetic women — is real but narrow and was publicly contested by other researchers 8. Head-to-head, no trial has raced the two precursors against each other; the honest comparison is record-versus-record, which we walk through trial by trial in NMN vs NR.

NAD+ itself — IV drips, subcutaneous injections, nasal sprays, patches — is where the evidence inverts against the price. These routes deliver the finished molecule while skipping the gut, and they are marketed accordingly. Small IV studies have assessed biochemistry, short-term safety and tolerability, including a retrospective pilot published in 2026 10. Those findings do not establish routine benefits for energy, cognition or aging. Subcutaneous/IM and nasal products have different evidence gaps; IV findings cannot validate those routes. Our route-by-route breakdown separates them. You pay the most for the route with the least evidence.

For the oral precursor trials, raising a biomarker does not guarantee that you will feel or function better. Trials that reliably elevate NAD+ keep failing to move the outcomes people buy these products for — a six-month randomized trial of NR in peripheral artery disease produced only a modest walking benefit 9, and the NMN literature's felt-benefit signals are small and scattered 5. The biology is genuine 6; the leap to "you will feel younger" is not yet supported.

The cost-per-dose reality

Sticker prices mislead in this category because doses vary tenfold. A fair comparison is cost per effective dose: label-dose NR and NMN capsules typically land in the tens of dollars per month, while prescription NAD+ routes on our index run from a $93-per-month advertised floor to several hundred dollars — for the routes with the least human evidence. Run your own numbers with the NMN vs NR cost-per-dose calculator, and see what every prescription provider actually publishes on the NAD+ price index.

Who each option is for

  • Choose oral NR if you want the option with the deepest human trial record — bioavailability, chronic dosing, and a branded-ingredient safety study 7 3 4 — at the lowest cost per month. Its side-effect profile is mild; we cover it in the NR side-effects guide.
  • Choose oral NMN if you prefer its specific trial literature or formulation options; it raises NAD+ dose-dependently and is well tolerated in trials 5. Dosing guidance is in our NMN dosage calculator.
  • Think hard before paying for NAD+ itself. If you are considering an IV, injection, or nasal route anyway — for the clinician contact, the protocol, or the format — go in knowing the evidence gap, and compare what each seller actually charges and discloses on our provider rankings. The ranked options there are compared on price transparency and clinical oversight, not on efficacy claims no route has earned.

Bottom line

NAD+ is the destination; NMN and NR are the two roads that verifiably get there by mouth. NR holds the deepest evidence file, NMN a genuine second, and "NAD+ itself" — for all its premium pricing — the thinnest. Start with the precursor comparison in NMN vs NR if you are choosing a supplement, or the evidence pillar if you want the full clinical picture before spending anything.

Frequently asked questions

What's the difference between NAD+, NMN, and NR?

NAD+ is the working molecule — the coenzyme your cells use for energy metabolism and DNA repair. NMN and NR are precursors: smaller molecules your cells convert into NAD+ (NR converts via NMN, which converts via one enzymatic step into NAD+). You cannot effectively swallow NAD+ itself — it is large, charged, and poorly absorbed — which is why the research field built its strategy around the precursors.

Which is better, NMN or NR?

No head-to-head human trial has raced them. On record depth, NR leads: it has proven oral bioavailability, chronic-dosing trials, and a dedicated placebo-controlled safety study of the branded NIAGEN ingredient at up to 1,000 mg/day. NMN has real randomized trials showing dose-dependent NAD+ increases and good tolerability. Both raise the biomarker; neither has proven the felt benefits the category markets.

Is taking NAD+ directly better than taking a precursor?

The evidence says the opposite of the pricing. Oral NAD+ faces absorption barriers the precursors avoid, and small IV studies of biochemistry, tolerability and safety do not establish routine benefits for energy, cognition or aging. Subcutaneous/IM and nasal products cannot borrow efficacy from IV findings. Precursors by mouth are the evidence-backed way to raise NAD+; the direct routes are the expensive, unproven way.

References

  1. Rajman L, Chwalek K, Sinclair DA (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/29514064/
  2. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  3. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  4. Conze D, Brenner C, Kruger CL (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/31278280/
  5. Yi L, Maier AB, Tao R (2023). The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
  6. Verdin E (2015). NAD+ in aging, metabolism, and neurodegeneration. Science. https://pubmed.ncbi.nlm.nih.gov/26785480/
  7. Trammell SA, Schmidt MS, Weidemann BJ, et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/27721479/
  8. Yoshino M, Yoshino J, Kayser BD, Klein S (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://pubmed.ncbi.nlm.nih.gov/33888596/
  9. McDermott MM, Martens CR, Domanchuk KJ, et al. (2024). Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38871717/
  10. Reyna K, Heinzen G, Patel N, et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. https://pubmed.ncbi.nlm.nih.gov/41704678/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.